Clinical Cancer Research The Science of Cancer Health Disparities Infection and Cancer: Biology, Therapeutics, and Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schindler, J.
Right arrow Articles by Vitetta, E. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schindler, J.
Right arrow Articles by Vitetta, E. S.
Clinical Cancer Research Vol. 7, 255-258, February 2001
© 2001 American Association for Cancer Research

Clinical Trials

The Toxicity of Deglycosylated Ricin A Chain-containing Immunotoxins in Patients with Non-Hodgkin’s Lymphoma Is Exacerbated by Prior Radiotherapy: A Retrospective Analysis of Patients in Five Clinical Trials1

John Schindler, Edward Sausville, Richard Messmann, Jonathan W. Uhr and Ellen S. Vitetta2

The Cancer Immunobiology Center and the Department of Microbiology, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75390 [J. S., J. W. U., E. S. V.], and the Developmental Therapeutics Program, National Cancer Institute, Bethesda, Maryland [E. S., R. M.]

A retrospective analysis of 102 patients with relapsed, non-Hodgkin’s lymphoma treated with two different ricin A chain-containing immunotoxins (ITs) in five Phase I clinical trials indicates that the dose-limiting toxicity, vascular leak syndrome, was more frequent and more severe in patients who had undergone prior radiotherapy (RT). Excluding patients with prior RT from the calculations of the maximum tolerated dose indicates that the maximum tolerated doses of these ITs had not been reached in any trial and are clearly higher than reported previously. Excluding patients with prior RT from future clinical trials may increase the dose of ITs that can be given in the absence of severe vascular leak syndrome.




This article has been cited by other articles:


Home page
 GutHome page
D A Vallera, B J Stish, Y Shu, H Chen, A Saluja, D J Buchsbaum, and S M Vickers
Genetically designing a more potent antipancreatic cancer agent by simultaneously co-targeting human IL13 and EGF receptors in a mouse xenograft model
Gut, May 1, 2008; 57(5): 634 - 641.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. Wang, J. Zhao, J.-L. Ren, L. Zhang, W.-H. Wen, R. Zhang, W.-W. Qin, L.-T. Jia, L.-B. Yao, Y.-Q. Zhang, et al.
Recombinant Immunoproapoptotic Proteins with Furin Site Can Translocate and Kill HER2-Positive Cancer Cells
Cancer Res., December 15, 2007; 67(24): 11830 - 11839.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Y.-H. Wu, S.-F. Shih, and J.-Y. Lin
Ricin Triggers Apoptotic Morphological Changes through Caspase-3 Cleavage of BAT3
J. Biol. Chem., April 30, 2004; 279(18): 19264 - 19275.
[Abstract] [Full Text] [PDF]

Home page
 Protein Eng Des SelHome page
M. A. Olson, J. H. Carra, V. Roxas-Duncan, R. W. Wannemacher, L. A. Smith, and C. B. Millard
Finding a new vaccine in the ricin protein fold
Protein Eng. Des. Sel., April 1, 2004; 17(4): 391 - 397.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. F. DiJoseph, D. C. Armellino, E. R. Boghaert, K. Khandke, M. M. Dougher, L. Sridharan, A. Kunz, P. R. Hamann, B. Gorovits, C. Udata, et al.
Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies
Blood, March 1, 2004; 103(5): 1807 - 1814.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
R. Schnell, P. Borchmann, J. O. Staak, J. Schindler, V. Ghetie, E. S. Vitetta, and A. Engert
Clinical evaluation of ricin A-chain immunotoxins in patients with Hodgkin's lymphoma
Ann. Onc., May 1, 2003; 14(5): 729 - 736.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. A. Posey, M. B. Khazaeli, M. A. Bookman, A. Nowrouzi, W. E. Grizzle, J. Thornton, D. E. Carey, J. M. Lorenz, A. P. Sing, C. B. Siegall, et al.
A Phase I Trial of the Single-Chain Immunotoxin SGN-10 (BR96 sFv-PE40) in Patients with Advanced Solid Tumors
Clin. Cancer Res., October 1, 2002; 8(10): 3092 - 3099.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Schnell, O. Staak, P. Borchmann, C. Schwartz, B. Matthey, H. Hansen, J. Schindler, V. Ghetie, E. S. Vitetta, V. Diehl, et al.
A Phase I Study with an Anti-CD30 Ricin A-Chain Immunotoxin (Ki-4.dgA) in Patients with Refractory CD30+ Hodgkin's and Non-Hodgkin's Lymphoma
Clin. Cancer Res., June 1, 2002; 8(6): 1779 - 1786.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. E. Frankel
Increased Sophistication of Immunotoxins
Clin. Cancer Res., April 1, 2002; 8(4): 942 - 944.
[Full Text] [PDF]

Home page
 IOVSHome page
S. P. Christiansen, D. Peterson, T. To, R. Youle, and L. McLoon
Long-term Effects of Ricin-mAb 35 on Extraocular Muscles of Rabbits: Potential Treatment for Strabismus
Invest. Ophthalmol. Vis. Sci., March 1, 2002; 43(3): 679 - 685.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2001 by the American Association for Cancer Research.